REAL-WORLD DOSING AND ADHERENCE IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH NABIXIMOLS IN GERMANY

被引：0
|
作者：
Freilich, J. [1 ]
Rodriguez-Rey, Delclaux M. [2 ]
Spelman, T. [3 ]
Yeramaneni, S. [4 ]
Drachenberg, C. [4 ]
机构：
[1] Parexel Int, Stockholm, AB, Sweden
[2] Parexel Int, London, England
[3] Karolinska Inst, Stockholm, Sweden
[4] Jazz Pharmaceut, Palo Alto, CA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
RWD86
引用
收藏
页码：S376 / S376
页数：1
相关论文
共 50 条
  • [21] Walk Your Talk: Real-World Adherence to Guidelines on the Use of MRI in Multiple Sclerosis
    Tortora, Mario
    Tranfa, Mario
    D'Elia, Anna Chiara
    Pontillo, Giuseppe
    Petracca, Maria
    Bozzao, Alessandro
    Caranci, Ferdinando
    Cervo, Amedeo
    Cosottini, Mirco
    Falini, Andrea
    Longo, Marcello
    Manara, Renzo
    Muto, Mario
    Porcu, Michele
    Roccatagliata, Luca
    Todeschini, Alessandra
    Saba, Luca
    Brunetti, Arturo
    Cocozza, Sirio
    Elefante, Andrea
    DIAGNOSTICS, 2021, 11 (08)
  • [22] The real-world outcomes of multiple myeloma patients treated with daratumumab
    Szabo, Agoston Gyula
    Klausen, Tobias Wirenfeldt
    Levring, Mette Boegh
    Preiss, Birgitte
    Helleberg, Carsten
    Breinholt, Marie Fredslund
    Hermansen, Emil
    Gjerdrum, Lise Mette Rahbek
    Bonlokke, Soren Thorgaard
    Nielsen, Katrine
    Kjeldsen, Eigil
    Iversen, Katrine Fladeland
    Teodorescu, Elena Manuela
    Dokhi, Marveh
    Kurt, Eva
    Strandholdt, Casper
    Andersen, Mette Klarskov
    Vangsted, Annette Juul
    PLOS ONE, 2021, 16 (10):
  • [23] REAL-WORLD OUTCOMES AND MEDICATION ADHERENCE TO DISEASE MODIFYING THERAPIES (DMTS) AMONG PATIENTS WITH MULTIPLE SCLEROSIS (MS)
    Grassi, D. M.
    Graham, J.
    Ye, X.
    Maeng, D.
    Frusciante, K.
    Nathanson, D. C.
    Burton, M.
    Wright, E.
    Gomes, J.
    Bao, Y.
    VALUE IN HEALTH, 2018, 21 : S203 - S203
  • [24] Real-world patient characteristics, treatment patterns and costs in relapsing multiple sclerosis patients treated with glatiramer acetate, dimethyl fumarate or teriflunomide in Germany
    Ziemssen, Tjalf
    Kurzeja, Anna
    Muresan, Bogdan
    Haas, Jennifer S.
    Alexander, Jessica
    Driessen, Maurice T.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2022, 12 (02) : 93 - 107
  • [25] Observational study to evaluate real-world effectiveness in multiple sclerosis patients treated with alemtuzumab in Germany: TREAT-MS study preliminary results
    Thomas, K.
    Leptich, A.
    Kern, R.
    Engelmann, U.
    Haase, R.
    Ziemssen, T.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 883 - 883
  • [26] Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab
    Beckers, L.
    Baeten, P.
    Popescu, V.
    Swinnen, D.
    Cardilli, A.
    Hamad, I.
    Wijmeersch, Van
    Tavernier, S. J.
    Kleinewietfeld, M.
    Broux, B.
    Fraussen, J.
    Somers, V.
    CLINICAL IMMUNOLOGY, 2024, 259
  • [27] Teriflunomide for multiple sclerosis in real-world setting
    Elkjaer, M. L.
    Molnar, T.
    Illes, Z.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 136 (05): : 447 - 453
  • [28] Real-world experiment of rituximab in multiple sclerosis
    Esmaeili, S.
    Motamed, M.
    Mirzaasgari, Z.
    Zamani, B.
    Joghatayi, M. T.
    Mojtahed, M.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [29] Walking improvements with nabiximols in patients with multiple sclerosis
    Coghe, G.
    Pau, M.
    Corona, F.
    Frau, J.
    Lorefice, L.
    Fenu, G.
    Spinicci, G.
    Mamusa, E.
    Musu, L.
    Massole, S.
    Massa, R.
    Marrosu, M. G.
    Cocco, E.
    JOURNAL OF NEUROLOGY, 2015, 262 (11) : 2472 - 2477
  • [30] Efficacy and discontinuation of nabiximols in patients with multiple sclerosis: a real-life study
    Bergamaschi, V.
    Konrad, G.
    Battaglia, M. A.
    Brichetto, G.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 959 - 959
12345